Merck stops testing combo drug for lung cancer
Adds details in paragraphs 2 and 6, background throughout
Aug 8 (Reuters) -Merck MRK.N said on Thursday it had discontinued a trial testing a combination immunotherapy treatmentin patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed.
The patients tested with a combination of its experimentaldrug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck said, adding that patients should stop ongoing treatment with the therapy.
The discontinuation marked yet another setback for vibostolimab and the promising new class of immunotherapies called anti-TIGIT to which it belongs.
Gilead Sciences GILD.O, Roche ROG.S and GSK GSK.L are among half a dozen drugmakers looking to grab a share of the lucrative anti-TIGIT cancer drug market, but the field has experienced multiplesetbacks.
Vibostolimab works by selectively binding itself to TIGIT, a receptor on immune cells, to activate the immune system against cancer cells and prevent a misguided immune attack against healthy cells.
Merck was testing vibostolimab along with Keytruda as a first-line treatment for patientswith extensive-stage small cell lung cancer in the late-stage study.
Last year, the combination therapy had failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments.
The drugmakerdiscontinued another late-stage study in May testing the combination therapy in patients with a severe form of skin cancer after side effects led to high discontinuation.
Reporting by Leroy Leo in Bengaluru; Editing by Devika Syamnath
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
